by | May 1, 2024 | Adams, Lucas, Diamond, Michael, Fremont, Daved, Raju, Saravanan
— VLDLR-based Decoy Receptors to Prevent Alphavirus Infections
Technology Description
Researchers at Washington University in St. Louis have developed very low-density lipoprotein receptor (VLDLR) soluble decoy receptors with potent inhibitory activity in vitro and in vivo. Eastern equine encephali…
by | Feb 13, 2024 | Chheda, Milan, Diamond, Michael, Gorman, Matthew
— T-017429 Engineered Oncolytic Zika Virus Therapy for Glioblastoma
Technology Description
Researchers in the laboratories of Michael Diamond and Milan Chheda at Washington University have developed prospective treatments for glioblastoma (GBM) through the application of an engineered Zika virus (ZI…
by | Feb 2, 2024 | Asadi Jomnani, Farzad, Dolle, Roland "Ron", Piston, David
— T-020153 – Small Molecule Agonists of EphA Receptors to Ameliorate Diabetes
Technology Description
Blood glucose levels (left), post-treatment plasma glucagon (center) in WCDD301 treated NOD (non-obese diabetic) mice with moderate hyperglycemia. Blood glucose levels (right) in Streptozotocin-ind…
by | Oct 13, 2023 | Dodson, Karen, Ellebedy, Ali, Feldman, Mario, Hultgren, Scott, Pinkner, Jerome, Tamadonfar, Kevin, Timm, Morgan
— Technology Description
Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
by | Jun 17, 2022 | Bowman, Brittany, Dolle, Roland "Ron", Lapak, Kyle, Major, Michael "Ben", Medcalf, Matthew
— Disease indication – Diseases related to oxidative stress, including cancer, autoimmune disease, and Toxoplasma infection
Drug format – Small molecule
Drug class – Best-in-class
Research stage and preliminary data – The researchers have synthesized a series of pyrimethamin…